Timothy M. Ring
Known title: DirectorCIK: 0001204666
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Transaction History
| DGX | ▲ Buy | Grant | 1,142 | $0 | 5/20/2026 | View on chart |
| BDX | ▲ Buy | Grant | 1,098 | $0 | 1/27/2026 | View on chart |
| DGX | ▲ Buy | Grant | 1,203 | $0 | 5/15/2025 | View on chart |
| BDX | ▲ Buy | Grant | 930 | $0 | 1/28/2025 | View on chart |
| DGX | ▲ Buy | Grant | 1,482 | $0 | 5/16/2024 | View on chart |
| BDX | ▲ Buy | Grant | 900 | $0 | 1/23/2024 | View on chart |
| DGX | ▲ Buy | Grant | 1,369 | $0 | 5/17/2023 | View on chart |
| BDX | ▲ Buy | Grant | 848 | $0 | 1/24/2023 | View on chart |
| DGX | ▲ Buy | Option Exercise | 972 | $60K | 12/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 1,053 | $56K | 12/1/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,025 | $309K | 12/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 260 | $16K | 11/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 1,371 | $83K | 11/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 369 | $23K | 11/1/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,000 | $288K | 11/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 2,000 | $122K | 10/3/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,000 | $247K | 10/3/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 2,000 | $122K | 9/1/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,000 | $250K | 9/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 149 | $8K | 8/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 1,851 | $113K | 8/1/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,000 | $272K | 8/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 1,010 | $57K | 7/1/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 990 | $58K | 7/1/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,000 | $267K | 7/1/2022 | View on chart |
| DGX | ▲ Buy | Grant | 1,292 | $0 | 5/18/2022 | View on chart |
| BDX | ▲ Buy | Grant | 820 | $0 | 1/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.